Last reviewed · How we verify
NCT05648799
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
NA trial testing GP30341 capsules 200 mg in Pharmacokinetics in 246 participants. Completed in 20 July 2022.
11 May 2022
Quick facts
| Lead sponsor | Geropharm |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 246 |
| Start date | 17 March 2022 |
| Primary completion | 11 May 2022 |
| Estimated completion | 20 July 2022 |
| Sites | 5 locations across Russia |
Drugs / interventions tested
- GP30341 capsules 200 mg — full drug profile →
- Standard therapy — full drug profile →
Conditions studied
- Pharmacokinetics — all drugs for Pharmacokinetics →
- Safety Issues — all drugs for Safety Issues →
- Efficacy — all drugs for Efficacy →
Sponsor
Geropharm — full company profile →
Who can join
18 and older, any sex, with Pharmacokinetics or Safety Issues. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pharmacokinetics, safety and efficacy study of GP30341, 200 mg capsules (GEROPHARM LLC, Russia) in healthy volunteers and patients with novel coronavirus infection 2019 (COVID-19) with a high risk of adverse outcome
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05648799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pharmacokinetics
Currently open trials in the same condition.
- NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
- NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
- NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
- NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
- NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting
Other Geropharm trials
Trials by the same sponsor.
- NCT06497049 — Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®. · Phase 1 · completed
- NCT07070752 — Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus · Phase 3 · completed
- NCT06497036 — Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia · Phase 3 · active not recruiting
- NCT05652595 — Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141 · Phase 1 · unknown
- NCT04226105 — Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05648799 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geropharm
- Last refreshed: 22 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05648799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing